A total of 200 patients were followed over 12 months, and findings indicated that SGLT-2 inhibitors improved blood pressure control, reduced cardiovascular events, and lowered heart failure hospitalizations, with variations observed between diabetic and non-diabetic groups. The gene discussed is SLC5A2; the disease is heart failure.